Investigators assessed the diagnostic performance of AST to Platelet Ratio Index and Fibrosis-4 scores compared with transient elastography evaluation of liver stiffness to detect significant fibrosis or cirrhosis.
Researchers suggest that novel biologicals should be explored as a treatment alternative to hepatitis vaccination for patients who are being treated with immunosuppressive drugs.
Adult heart transplants from hepatitis C virus-positive (HCV+) donors appear safe, with no increased risk for adverse effects on one-year survival.
Researchers found data that showed schistosomiasis does not escalate liver damage in patients who are infected with the hepatitis B virus.
From a nationwide Swedish registry, researchers found data that showed in patients with hepatitis B or C virus infection, the long-term hepatocellular carcinoma risk was lower in patients who were treated with lipophilic statins.
Investigators found data that showed patients with hepatitis C virus infection who had a sustained viral response to treatment with interferon had less incidence of extrahepatic manifestations.
Drug interactions between antiretroviral therapy (ART) and direct-acting antivirals (DAAs) pose a clinical challenge in patients with HIV/hepatitis C virus (HCV) coinfection.
Researchers found data that showed less than 10% of people diagnosed with chronic hepatitis C virus infection received treatment with DAAs.
Several physicians explore the etiology of osteopenia and osteoporosis in patients with HIV and HCV who are undergoing antiretroviral therapy.
In Canada, researchers found data that showed there is a need for mental health and addiction care for patients with hepatitis C infection.
In China, researchers found data that showed DAA-based therapies are safe in treating chronic hepatitis C.
Patients with hepatitis C virus (HCV) and cirrhosis can develop high-risk gastroesophageal varices (GEV) after sustained virological response (SVR). Surveillance is especially recommended in those with GEV before antiviral treatment.
A multicomponent intervention can improve hepatitis C virus (HCV) screening, although there is considerable variation by practice.
Of the 6 vascular injury markers measured, soluble vascular cell adhesion molecule 1 showed the strongest correlation with disease parameters.
Dried blood spot specimens could be a reliable alternative testing specimen, which may increase hepatitis B and C diagnostic opportunities for rural, remote, and hard to reach regions.
Researchers found data that showed patients who have or who are injecting drugs would benefit from treatment for HCV with direct-acting antivirals.
Researchers found data that showed in countries with low or middle incomes the burden of hepatitis C virus infection has increased the risk for cardiovascular disease.
At centers in Asia, Europe, and the Americas, investigators conducted a randomized controlled trial of patients with chronic hepatitis B virus infection to assess the long-term effects of entecavir.
Researchers report on use of the short-duration, pangenotypic, ribavirin-free regimen in adolescents with chronic HCV infection.
The FDA has approved updated labeling for Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir) to include updated information regarding treatment of patients with hepatitis C virus (HCV) who have severe renal impairment including those with end stage renal disease who are on dialysis.